| Disorders of Sex Development (MESH:D012734) (5) |
CYP19A1 (202); HSD17B3 (27); LHB (83); LHCGR (34); NR3C1 (189) |
7.48 |
17.21 |
27.02 |
22.04 |
17.10 |
| Muscular Dystrophy, Facioscapulohumeral (MESH:D020391) (9) |
CDKN1A (375); DCN (49); ELN (32); HSPA1B (84); LUM (25) |
5.42 |
12.51 |
27.77 |
20.21 |
12.45 |
| Osteosarcoma (MESH:D012516) (11) |
CYP3A4 (414); FOLR1 (39); JUN (305); NR1I2 (216); TP53 (458) |
4.88 |
11.27 |
22.54 |
16.91 |
11.38 |
| Metabolic Syndrome X (MESH:D024821) (16) |
ADIPOQ (89); CCL2 (283); LEP (106); SHBG (48); TRIB3 (51) |
3.96 |
9.19 |
26.30 |
18.36 |
10.27 |
| Precancerous Conditions (MESH:D011230) (20) |
CCND1 (327); IRS1 (47); MAPK8 (200); MAPK9 (109); PTGS2 (521) |
3.46 |
8.05 |
23.44 |
15.74 |
8.19 |
| Myocardial Reperfusion Injury (MESH:D015428) (22) |
ADIPOG (89); EDN1 (186); NOS2 (456); PTEN (100); SLC8A1 (31) |
3.25 |
7.59 |
25.19 |
16.39 |
7.75 |
| Drug Hypersensitivity (MESH:D004342) (22) |
ABCC2 (204); HSPA1A (122); IL4 (228); IL4RA (17); TNF (835) |
3.25 |
7.59 |
24.13 |
15.86 |
7.74 |
| Limb Deformities, Congenital (MESH:D017880) (25) |
CACNA1C (23); FGFR2 (90); HOXA11 (22); TBX3 (21); TGFB2 (70) |
2.98 |
6.98 |
30.32 |
18.98 |
7.41 |
| Carcinoma (MESH:D002277) (25) |
BCL2 (443); EGFR (204); KRAS (79); PTGS2 (521); TARBP2 (11) |
2.98 |
6.98 |
24.73 |
15.86 |
7.14 |
| Endometrial Neoplasms (MESH:D016889) (34) |
BIRC5 (167); DCN (49); HOXA11 (22); PTEN (100); SUZ12 (13) |
2.37 |
5.62 |
29.24 |
17.79 |
6.07 |
| Cleft Lip (MESH:D002971) (28) |
FGFR1 (73); FGFR2 (90); FGFR3 (60); SPRY2 (19); TYMS (113) |
2.75 |
6.46 |
28.09 |
17.28 |
5.83 |
| Leukemia, Promyelocytic, Acute (MESH:D015473) (34) |
AKT1 (315); CD44 (70); CEBPA (78); ITGB2 (46); RARA (81) |
2.37 |
5.62 |
26.32 |
15.97 |
5.81 |
| Dermatitis, Atopic (MESH:D003876) (37) |
CXCL10 (87); IFNG (347); IL1B (492); IL4 (228); TSLP (18) |
2.21 |
5.27 |
24.37 |
14.82 |
5.44 |
| Neuroblastoma (MESH:D009447) (39) |
IFNB1 (48); MET (61); MYC (253); MYCN (31); NTRK2 (37) |
2.11 |
5.05 |
28.09 |
16.57 |
5.26 |
| Glioblastoma (MESH:D005909) (42) |
IL1B (492); MMP2 (194); NCOR1 (39); TGM2 (75); VEGFA (271) |
1.97 |
4.76 |
24.17 |
14.46 |
4.94 |
| Cardiovascular Diseases (MESH:D002318) (43) |
CBS (24); CCL2 (283); EDN1 (186); GH1 (70); VCAM1 (123) |
1.93 |
4.67 |
25.86 |
15.27 |
4.86 |
| Liver Cirrhosis (MESH:D00103) (49) |
CTGF (77); FGFR2 (90); MMP2 (194); SPP1 (113); THBS1 (68) |
1.70 |
4.18 |
25.90 |
15.04 |
4.38 |
| Colitis, Ulcerative (MESH:D003093) (50) |
GNA12 (18); IL12B (194); IL1B (492); PTPN2 (18); STAT3 (127) |
1.67 |
4.11 |
26.77 |
15.44 |
4.32 |
| Cell Transformation, Neoplastic (MESH:D002471) (60) |
NOS2 (456); SLC16A1 (73); SLC2A1 (88); TSC22D1 (46); WNT5A (38) |
1.37 |
3.48 |
26.52 |
15.00 |
3.70 |
| Lupus Erythematosus, Systemic (MESH:D008180) (62) |
CLU (115); ETS1 (35); FASLG (72); IL12B (194); IL4 (228) |
1.32 |
3.38 |
25.71 |
14.55 |
3.58 |
| Kidney Diseases (MESH:D007674) (71) |
CDKN1A (375); HOXA11 (22); LCN2 (64); LRP2 (19); TERT (80) |
1.11 |
2.97 |
28.15 |
15.56 |
3.20 |
